Jiangsu CoWin Biotech's high P/S ratio may be unjustified du...
Jiangsu CoWin Biotech's high P/S ratio may be unjustified due to its poor financial performance and declining revenue. If the company's medium-term revenue trends persist, it could pose a risk to the share price and potential investors.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000236a055a8253e8.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment